CN109806271B - Pharmaceutical composition for treating allergic dermatitis and preparation thereof - Google Patents
Pharmaceutical composition for treating allergic dermatitis and preparation thereof Download PDFInfo
- Publication number
- CN109806271B CN109806271B CN201910110302.7A CN201910110302A CN109806271B CN 109806271 B CN109806271 B CN 109806271B CN 201910110302 A CN201910110302 A CN 201910110302A CN 109806271 B CN109806271 B CN 109806271B
- Authority
- CN
- China
- Prior art keywords
- allergic dermatitis
- pharmaceutical composition
- catalpol
- parts
- fexofenadine hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention relates to a pharmaceutical composition for treating allergic dermatitis and a preparation thereof, the pharmaceutical composition for treating allergic dermatitis comprises iridoid compounds and optional antihistamine compounds as active ingredients, can effectively relieve various symptoms of allergic dermatitis such as pruritus and the like, the iridoid is combined with antihistamine, the effect of treating the allergic dermatitis is more excellent, the administration dosage of the antihistamine is reduced, the side effect is reduced, the administration frequency of the medicament can be further reduced after the iridoid is prepared into a slow-release preparation, the stable blood concentration is maintained, the side effect of the medicament can be further reduced, and therefore the pharmaceutical composition for treating the allergic dermatitis is effective and safe.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a pharmaceutical composition for treating allergic dermatitis and a preparation thereof.
Background
Allergic dermatitis, which is a disease in which skin is allergic due to contact with allergen, belongs to type I allergy and is mainly mediated by IgE. The causes of allergic dermatitis may be related to infection, food or drugs, and the allergic dermatitis includes different types such as contact dermatitis, neurodermatitis, solar dermatitis, seborrheic dermatitis, hormone-dependent dermatitis and the like according to the causes. The skin of the patient presents symptoms such as red swelling, pruritus, molting, wheezy and the like, and the life of the patient is seriously influenced. Although ideal treatment schemes for allergic dermatitis are allergen elimination, immunological repair of patients, symptomatic treatment of symptoms of allergic dermatitis, and standardized immunotherapy with desensitizing agents, since the number of allergens is too large, the number of known allergens exceeds 2 million, and thus, accurate allergens are often difficult to determine. Therefore, currently, antihistamine drugs such as chlorpheniramine, loratadine or corticosteroid hormones are generally adopted to treat allergic dermatitis clinically, although symptoms related to the allergic dermatitis can be relieved, the treatment effect is poor, patients easily relapse, various side effects such as dizziness, somnolence, hypodynamia, dry mouth and central obesity exist, and the patients cannot take the medicine for a long time.
The iridoid compound is a cyclic monoterpene compound containing the following cyclopentane structural unit
The compound has wide biological activity, such as anticancer, blood sugar reducing, blood pressure lowering, organism immunity enhancing, liver protecting, anti-inflammatory, anti-oxidation, neuroprotection and the like, and becomes a research hotspot for treating various diseases, but no report for treating allergic dermatitis by using iridoid compounds is found at present.
The invention aims to treat allergic dermatitis by using iridoid compounds, thereby providing a pharmaceutical composition for treating allergic dermatitis.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition for treating allergic dermatitis.
Specifically, the invention provides a pharmaceutical composition for treating allergic dermatitis, which comprises iridoid compounds and optional antihistamine compounds as active ingredients.
Preferably, the iridoid compound is selected from:
or catalpol, more preferably, the iridoid compound is catalpol.
Preferably, the pharmaceutical composition for treating allergic dermatitis takes iridoid compounds as the only active ingredients;
preferably, the allergic dermatitis is selected from: atopic dermatitis, eczema, urticaria, and the like.
Preferably, the pharmaceutical composition for treating allergic dermatitis comprises a combination of iridoid and antihistamine compound as the only active ingredients.
Preferably, the antihistamine compound is selected from the group consisting of: chlorpheniramine, diphenhydramine, terfenadine, loratadine, fexofenadine, levocetirizine, and mixtures thereof; more preferably, the antihistamine is selected from loratadine, fexofenadine, or mixtures thereof; most preferably, the antihistamine is fexofenadine.
Preferably, the fexofenadine is selected from fexofenadine hydrochloride.
The weight ratio of the iridoid compound to the antihistamine compound is 3-10: 2-6; preferably, the weight ratio of the iridoid compound to the antihistamine compound is 4-8: 3-5; more preferably, the weight ratio of the iridoid compound to the antihistamine compound is 5: 4.
preferably, the iridoid compound and the optional antihistamine compound in the pharmaceutical composition of the invention account for 1-90% of the total weight of the pharmaceutical composition; preferably, the iridoid compound and the optional antihistamine compound in the pharmaceutical composition of the invention account for 3-60% of the total weight of the pharmaceutical composition; more preferably, the iridoid compound and the optional antihistamine compound in the pharmaceutical composition of the invention account for 5-30% of the total weight of the pharmaceutical composition; most preferably, the iridoid compound and the optional antihistamine compound in the pharmaceutical composition of the invention comprise 10% of the total weight of the pharmaceutical composition.
The pharmaceutical composition for treating allergic dermatitis according to the present invention can be administered parenterally, parenterally or topically, preferably, the pharmaceutical composition for gastrointestinal administration is selected from: tablets, capsules, granules, powders, pills, solutions and the like; the pharmaceutical composition for parenteral administration is selected from injection, freeze-dried powder injection, infusion solution and the like; the topically administered pharmaceutical composition is selected from: creams, ointments, lotions, aerosols, patches, cataplasms and the like; preferably, the pharmaceutical composition for treating allergic dermatitis of the present invention is selected from: tablets or capsules;
preferably, the pharmaceutical composition for treating allergic dermatitis is a sustained-release preparation, and comprises iridoid compounds and optional antihistamine compounds as active ingredients and a skeleton sustained-release material.
Preferably, the sustained-release preparation is a sustained-release tablet or a sustained-release capsule; the skeleton slow-release material is selected from: an erodible matrix material, a hydrophilic gel slow release material, an insoluble matrix material, or a mixture thereof; more preferably, the erodible matrix material is selected from the group consisting of: stearic acid or polyethylene glycol; the hydrophilic gel slow-release material is selected from: hydroxypropyl methylcellulose, alginate, guar gum, or chitosan; the insoluble framework material is selected from: ethyl cellulose or acrylic resins.
Preferably, the skeleton slow-release material is a mixture of an erodible skeleton material and a hydrophilic gel slow-release material or a mixture of a hydrophilic gel slow-release material and an insoluble skeleton material; more preferably, the matrix sustained-release material is a mixture of polyethylene glycol and hydroxypropyl methyl cellulose or a mixture of hydroxypropyl methyl cellulose and ethyl cellulose; more preferably, the weight ratio of the polyethylene glycol to the hydroxypropyl methylcellulose is: 1-5: 6-15, wherein the weight ratio of the hydroxypropyl methyl cellulose to the ethyl cellulose is 5-15: 3-6; most preferably, the weight ratio of the polyethylene glycol to the hydroxypropyl methylcellulose is: 3: 10, wherein the weight ratio of the hydroxypropyl methyl cellulose to the ethyl cellulose is 9: 4.
in a further aspect, the invention provides the use of iridoid compounds in the preparation of a pharmaceutical composition for treating allergic dermatitis.
Preferably, the iridoid compound is selected from:
or catalpol, more preferably, the iridoid compound is catalpol.
Preferably, the allergic dermatitis is selected from: atopic dermatitis, eczema, urticaria, and the like.
In another aspect, the present invention provides the use of a combination of an iridoid compound and an antihistamine compound for the preparation of a pharmaceutical composition for the treatment of allergic dermatitis.
Preferably, the iridoid compound is selected from:
or catalpol, more preferably, the iridoid compound is catalpol.
Preferably, the antihistamine compound is selected from the group consisting of: chlorpheniramine, diphenhydramine, terfenadine, loratadine, fexofenadine, levocetirizine, and mixtures thereof; more preferably, the antihistamine is selected from loratadine, fexofenadine, or mixtures thereof; most preferably, the antihistamine is fexofenadine. Preferably, the fexofenadine is selected from fexofenadine hydrochloride.
Preferably, the allergic dermatitis is selected from: atopic dermatitis, eczema, urticaria, and the like.
The weight ratio of the iridoid compound to the antihistamine compound is 3-10: 2-6; preferably, the weight ratio of the iridoid compound to the antihistamine compound is 4-8: 3-5; more preferably, the weight ratio of the iridoid compound to the antihistamine compound is 5: 4.
in a further aspect, the invention provides the use of an iridoid compound in the preparation of an anti-pruritus pharmaceutical composition.
Preferably, the iridoid compound is selected from:
or catalpol, more preferably, the iridoid compound is catalpol.
In another aspect, the present invention provides the use of a combination of an iridoid compound and an antihistamine compound for the manufacture of an anti-pruritic pharmaceutical composition.
Preferably, the iridoid compound is selected from:
or catalpol, more preferably, the iridoid compound is catalpol.
Preferably, the antihistamine compound is selected from the group consisting of: chlorpheniramine, diphenhydramine, terfenadine, loratadine, fexofenadine, levocetirizine, and mixtures thereof; more preferably, the antihistamine is selected from loratadine, fexofenadine, or mixtures thereof; most preferably, the antihistamine is fexofenadine. Preferably, the fexofenadine is selected from fexofenadine hydrochloride.
The weight ratio of the iridoid compound to the antihistamine compound is 3-10: 2-6; preferably, the weight ratio of the iridoid compound to the antihistamine compound is 4-8: 3-5; more preferably, the weight ratio of the iridoid compound to the antihistamine compound is 5: 4.
the invention has the beneficial effects
The catalpol is confirmed to have an obvious effect of resisting allergic dermatitis through pharmacological experiments, the symptoms of pruritus and the like of patients with allergic dermatitis can be effectively relieved, the administration dosage of antihistamine can be effectively reduced after the catalpol is combined with antihistamine compounds, the side effect of the antihistamine compounds can be effectively reduced while the synergistic effect is achieved, after the pharmaceutical composition is prepared into a sustained-release dosage form, the administration frequency can be effectively reduced, the stable blood concentration is maintained, the side effect of the pharmaceutical composition is further reduced, and therefore the pharmaceutical composition for effectively and safely treating allergic dermatitis is provided.
Detailed Description
The present invention is described in more detail below to facilitate an understanding of the present invention.
Example 1A tablet for treating allergic dermatitis
Catalpol 7 parts, microcrystalline cellulose 40 parts, lactose 10 parts, sodium carboxymethylcellulose 8 parts, crospovidone 4 parts and magnesium stearate 0.5 part, and the preparation method comprises the following steps:
(1) preparing materials: weighing the raw materials according to the formula ratio, crushing catalpol, and sieving with a 40-mesh sieve to obtain catalpol powder for later use;
(2) tabletting: and (2) mixing the catalpol powder obtained in the step (1) with microcrystalline cellulose, lactose, carboxymethyl cellulose and crospovidone uniformly, performing wet granulation, sieving with a 12-mesh sieve, grading, adding magnesium stearate, mixing uniformly, and tabletting to obtain the tablet for treating allergic dermatitis.
Example 2A tablet for treating allergic dermatitis
Catalpol 5 parts, fexofenadine hydrochloride 4 parts, microcrystalline cellulose 50 parts, lactose 15 parts, sodium carboxymethylcellulose 10 parts, crospovidone 5 parts and magnesium stearate 0.5 part, and the tablets for treating allergic dermatitis are prepared according to the method of the example 1.
Example 3: capsule for treating allergic dermatitis
5 parts of catalpol, 4 parts of fexofenadine hydrochloride, 50 parts of microcrystalline cellulose, 15 parts of lactose, 10 parts of sodium carboxymethylcellulose, 5 parts of crospovidone and 0.5 part of magnesium stearate, and the preparation method comprises the following steps:
(1) preparing materials: weighing the raw materials according to the formula ratio, respectively crushing catalpol and fexofenadine hydrochloride, sieving with a 40-mesh sieve, and uniformly mixing to obtain mixed powder for later use;
(2) granulating and filling: and (2) uniformly mixing the mixed powder obtained in the step (1) with microcrystalline cellulose, lactose, carboxymethyl cellulose and crospovidone, performing wet granulation, sieving with a 12-mesh sieve, grading, adding magnesium stearate, uniformly mixing, and filling into a gelatin capsule shell to obtain the tablet for treating allergic dermatitis.
Example 4: sustained-release tablet for treating allergic dermatitis
5 parts of catalpol, 4 parts of fexofenadine hydrochloride, 15 parts of polyethylene glycol, 50 parts of hydroxypropyl methyl cellulose, 10 parts of sodium carboxymethyl cellulose, 5 parts of crospovidone and 0.5 part of magnesium stearate, and the preparation method comprises the following steps:
(1) preparing materials: weighing the raw materials according to the formula ratio, respectively crushing catalpol and fexofenadine hydrochloride, sieving with a 40-mesh sieve, and uniformly mixing to obtain mixed powder for later use;
(2) tabletting: and (2) uniformly mixing the mixed powder obtained in the step (1) with polyethylene glycol, hydroxypropyl methylcellulose, carboxymethyl cellulose and crospovidone, performing wet granulation, sieving with a 12-mesh sieve, granulating, adding magnesium stearate, uniformly mixing, and tabletting to obtain the sustained-release tablet for treating allergic dermatitis.
Example 5: sustained-release capsule for treating allergic dermatitis
Catalpol 6 parts, fexofenadine hydrochloride 3 parts, ethyl cellulose 20 parts, hydroxypropyl methyl cellulose 45 parts, sodium carboxymethyl cellulose 10 parts, crospovidone 5 parts and magnesium stearate 0.5 part, and the preparation method comprises the following steps:
(1) preparing materials: weighing the raw materials according to the formula ratio, respectively crushing catalpol and fexofenadine hydrochloride, sieving with a 40-mesh sieve, and uniformly mixing to obtain mixed powder for later use;
(2) tabletting: and (2) uniformly mixing the mixed powder obtained in the step (1) with ethyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose and crospovidone, performing wet granulation, sieving with a 12-mesh sieve, grading, adding magnesium stearate, uniformly mixing, and filling into a gelatin capsule shell to obtain the slow-release capsule for treating allergic dermatitis.
Effect example 1: iridoid compound and treatment effect of combination of iridoid compound and antihistamine compound on delayed hypersensitivity of dinitrofluorobenzene-induced mice
1.1 Experimental drugs:
(1) verbascoside, (2) catalpol, (3) loratadine, and (4) fexofenadine hydrochloride;
(5) verbascoside: loratadine ═ 1: 1. (6) verbascoside: loratadine ═ 5: 4. (7) verbascoside: loratadine ═ 5: 3. (8) verbascoside: loratadine ═ 5: 2. (9) verbascoside: loratadine ═ 5: 1;
(10) verbascoside: fexofenadine hydrochloride ═ 1: 1. (11) verbascoside: fexofenadine hydrochloride ═ 5: 4. (12) verbascoside: fexofenadine hydrochloride ═ 5: 3. (13) verbascoside: fexofenadine hydrochloride ═ 5: 2. (14) verbascoside: fexofenadine hydrochloride ═ 5: 1;
(15) catalpol: loratadine ═ 1: 1. (16) catalpol: loratadine ═ 5: 4. (17) catalpol: loratadine ═ 5: 3. (18) catalpol: loratadine ═ 5: 2. (19) catalpol: loratadine ═ 5: 1;
(20) catalpol: fexofenadine hydrochloride ═ 1: 1. (21) catalpol: fexofenadine hydrochloride ═ 5: 4. (22) catalpol: fexofenadine hydrochloride ═ 5: 3. (23) catalpol: fexofenadine hydrochloride ═ 5: 2. (24) catalpol: fexofenadine hydrochloride ═ 5: 1;
the above experimental drugs were prepared into 200mg/100mL liquid with physiological saline for use.
1.2 Experimental methods
And (3) randomly dividing 130 male Kunming mice into 26 groups, specifically a blank group, a model group and 1-24 drug groups, after adaptive feeding for 1d, performing intragastric administration of corresponding experimental drugs, wherein the intragastric administration volume is 0.4mL, the intragastric administration is performed for 1 time every day, and the intragastric administration is performed for 10d continuously, wherein the blank group and the model group are infused with physiological saline with the same amount as the intragastric administration.
4d, injecting 50 mu L of dinitrofluorobenzene solution 15g/L subcutaneously on the back of each group of mice outside the blank group, and injecting equal amount of normal saline subcutaneously in the blank group; the right ear of each group of mice was smeared with 30. mu.l of 10g/L dinitrofluorobenzene solution at the 9 th intragastric administration, and the blank group was smeared with the same amount of physiological saline. 2h after the last gastric lavage, the mice are killed by breaking the neck, the left and right ears of the mice are respectively taken to be made into ears with the diameter of 9mm, the ears are respectively weighed, the swelling rate is calculated, the specific experimental results are shown in table 1,
wherein the swelling ratio (%) - (right ear weight-left ear weight)/left ear weight × 100% was 100%.
1.3 results of the experiment
Data analysis was performed using the multi-factor analysis of variance module of statistical software SPSS, where P <0.05 indicates that the difference is statistically significant.
The experimental results in table 1 show that although the iridoid compounds verbascoside and catalpol have weaker effect on inhibiting the delayed type hypersensitivity reaction of dinitrofluorobenzene induced mice than loratadine and fexofenadine hydrochloride, the iridoid compounds verbascoside and catalpol also have obvious effect on inhibiting the delayed type hypersensitivity reaction of dinitrofluorobenzene induced mice. The mixture group of verbascoside, catalpol, loratadine and fexofenadine hydrochloride shows certain synergistic effect, such as verbascoside: loratadine ═ 5: 4, although the amount of the drug alone is reduced, it is inhibited
TABLE 1 swelling inhibition of delayed hypersensitivity in mice by dinitrofluorobenzene
# P <0.01 compared to blank group, # P <0.05 compared to model group, # P < 0.01.
The effect of dinitrofluorobenzene on delayed type hypersensitivity in mice is increased compared to either verbascoside or loratadine alone and exhibits a dose-dependent effect when the iridoid compound: antihistamine compounds ═ 5: 4, the effect is most excellent, wherein catalpol: fexofenadine hydrochloride ═ 5: the synergistic effect is most obvious when 4 hours, and is obviously superior to that of catalpol or fexofenadine hydrochloride alone, which suggests that catalpol and fexofenadine hydrochloride show synergistic effect when the catalpol and fexofenadine hydrochloride are combined according to the weight ratio.
Effect example 2: iridoid compound and combination of iridoid compound and antihistamine compound for treating histamine induced guinea pig pruritus
2.1 Experimental drugs
(1) Verbascoside, (2) catalpol, (3) loratadine, (4) fexofenadine hydrochloride, (5) catalpol: fexofenadine hydrochloride ═ 5: 4;
the above experimental drugs were prepared into 200mg/100mL liquid with physiological saline for use.
2.2 Experimental methods
30 guinea pigs with weight of 210-2The depilated area was cleaned and wiped dry, and the depilated area was abraded to a mild bleeding with sandpaper, using 0.02% histamine phosphate every 3 minutesThe total volume of histamine phosphate applied to the site of 50. mu.L of the site was recorded and the results are shown in Table 2.
2.3 results of the experiment
Data analysis was performed using the multi-factor analysis of variance module of statistical software SPSS, where P <0.05 indicates that the difference is statistically significant.
The experimental results in table 2 show that the volume of itch-causing histamine phosphate in guinea pigs with the iridoid compounds of verbascoside and catalpol group is obviously higher than that in the model group, and the content of itch-causing histamine phosphate in the guinea pigs with the iridoid compounds of verbascoside and catalpol group is remarkably higher than that in the model group, so that the content of itch-causing histamine phosphate in both verbascoside and catalpol group is relatively higher than that in loratadine and fexofenadine hydrochloride, while the content of itch-causing histamine phosphate in: fexofenadine hydrochloride ═ 5: the volume of histamine phosphate itch in the 4 groups of guinea pigs reached 350 μ L, which was significantly higher than 260 μ L in the catalpol group of guinea pigs and 310 μ L of fexofenadine hydrochloride, indicating a 5: 4, when catalpol and fexofenadine hydrochloride are applied according to the proportion, the anti-itch effect is obviously enhanced, so that the medicine can be used for anti-itch treatment of allergic dermatitis.
TABLE 2 Histamine phosphate-induced volume of itching in guinea pigs
| Sample size | Volume of phosphoric acid histamine for itch (μ L) | |
| Model set | 5 | 130±27.39 |
| Medicine 1 group | 5 | 190±22.36* |
| Medicine 2 group | 5 | 260±41.83* |
| Medicine 3 groups | 5 | 290±22.36* |
| Medicine 4 groups | 5 | 310±41.83** |
| Medicine 5 groups | 5 | 350±61.24** |
P <0.05, P <0.01 compared to model groups.
Effect example 3: dissolution rate determination method of pharmaceutical composition for treating allergic dermatitis
3.1 Experimental drugs
The invention provides a tablet for treating allergic dermatitis in example 2 and a sustained-release tablet for treating allergic dermatitis in example 3.
3.2 Experimental methods
Taking fexofenadine hydrochloride as a model, determining the dissolution rate by adopting a small cup method in a method for determining the dissolution rate and the release rate in the second part of Chinese pharmacopoeia 2015, and referring to the specific experimental results in table 3.
3.3 results of the experiment
TABLE 3 dissolution test results of fexofenadine hydrochloride in the pharmaceutical composition for treating allergic dermatitis according to the present invention
"-" indicates not determined.
The experimental results in table 3 show that fexofenadine hydrochloride in the tablet for treating allergic dermatitis according to example 2 of the present invention is substantially completely dissolved in 5min, whereas fexofenadine hydrochloride in the sustained-release tablet for treating allergic dermatitis according to example 3 of the present invention is only dissolved in 5.67% in 5min and 86.27% in 12h, showing a significant sustained-release effect, thereby facilitating the maintenance of drug effect for a long time and reducing the administration frequency.
The foregoing describes preferred embodiments of the present invention, but is not intended to limit the invention thereto. Modifications and variations of the embodiments disclosed herein may be made by those skilled in the art without departing from the scope and spirit of the invention.
Claims (6)
1. A pharmaceutical composition for treating allergic dermatitis is characterized in that the combination of catalpol and fexofenadine hydrochloride is taken as the only active ingredient, wherein the weight ratio of catalpol to fexofenadine hydrochloride is 5: 4.
2. the pharmaceutical composition for treating allergic dermatitis according to claim 1, wherein the dosage form of the pharmaceutical composition is selected from the group consisting of: tablet, capsule, granule, powder, pill, injection, lyophilized powder for injection, emulsion, ointment, lotion, aerosol, patch, and cataplasma.
3. The pharmaceutical composition for treating allergic dermatitis according to claim 1, wherein the dosage form of the pharmaceutical composition is infusion solution.
4. The pharmaceutical composition for treating allergic dermatitis according to claim 2, wherein the tablet is a sustained release tablet prepared from 5 parts of catalpol, 4 parts of fexofenadine hydrochloride, 15 parts of polyethylene glycol, 50 parts of hydroxypropyl methylcellulose, 10 parts of sodium carboxymethylcellulose, 5 parts of crospovidone and 0.5 part of magnesium stearate according to the following method:
(1) preparing materials: weighing the raw materials according to the formula ratio, respectively crushing catalpol and fexofenadine hydrochloride, sieving with a 40-mesh sieve, and uniformly mixing to obtain mixed powder for later use;
(2) tabletting: and (2) uniformly mixing the mixed powder obtained in the step (1) with polyethylene glycol, hydroxypropyl methylcellulose, sodium carboxymethylcellulose and crospovidone, performing wet granulation, sieving with a 12-mesh sieve, granulating, adding magnesium stearate, uniformly mixing, and tabletting to obtain the tablet.
5. The use of the combination of catalpol and fexofenadine hydrochloride as the only active ingredient in the preparation of a pharmaceutical composition for treating allergic dermatitis, wherein the weight ratio of catalpol to fexofenadine hydrochloride is 5: 4.
6. use according to claim 5, characterized in that said treatment of allergic dermatitis is anti-allergic dermatitis pruritus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910110302.7A CN109806271B (en) | 2019-02-11 | 2019-02-11 | Pharmaceutical composition for treating allergic dermatitis and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910110302.7A CN109806271B (en) | 2019-02-11 | 2019-02-11 | Pharmaceutical composition for treating allergic dermatitis and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109806271A CN109806271A (en) | 2019-05-28 |
| CN109806271B true CN109806271B (en) | 2020-06-26 |
Family
ID=66606428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910110302.7A Active CN109806271B (en) | 2019-02-11 | 2019-02-11 | Pharmaceutical composition for treating allergic dermatitis and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109806271B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100366264C (en) * | 2003-07-03 | 2008-02-06 | 和记黄埔医药企业有限公司 | Cornel extract and use thereof |
| CN100349589C (en) * | 2003-12-22 | 2007-11-21 | 罗何生 | Medical application of rehmannia root extractive in resisting asthma and allergy |
| CN100522983C (en) * | 2004-03-11 | 2009-08-05 | 罗何生 | Medical use of catalpol and its homologs |
-
2019
- 2019-02-11 CN CN201910110302.7A patent/CN109806271B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 羧甲基纤维素钠的研究进展;吴淑茗等;《化学工程与装备》;20181031(第10期);第246-247页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109806271A (en) | 2019-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101099729B (en) | Oral solid preparation containing ambroxol hydrochloride and salbutamol active components | |
| WO2016029868A1 (en) | Composition and medicinal product for reducing body weight and body fat, and use of said product | |
| CN101069675A (en) | A method of alleviating signs and symptons of spasticity | |
| EP0631782A1 (en) | Stabilized solid pharmaceutical preparation containing dextromethorphan, phenylpropanolamine and caffeine | |
| CN1621041A (en) | Pharmaceutical composition with pain easing function | |
| CN101006989A (en) | Slow release preparation of alginic sodium diester | |
| KR20140019445A (en) | Compound chemical medicine acting on respiratory disease, preparation process and use thereof | |
| CN104922143B (en) | The composition and its preparation method and application of EGCG and chitosan oligosaccharide | |
| CN101099730A (en) | Oral solid preparation containing ambroxol hydrochloride and guaifenesin active components | |
| CN109806271B (en) | Pharmaceutical composition for treating allergic dermatitis and preparation thereof | |
| CN102917695A (en) | Atazanavir sulfate formulations with improved ph effect | |
| CN115154551B (en) | Pharmaceutical composition containing famotidine for relieving stomach discomfort and preparation method thereof | |
| EP2148660A2 (en) | Sustained release | |
| CN107982268A (en) | A kind of tolvaptan preparation and its application | |
| CN103222966A (en) | Solid pharmaceutical composition containing Fingolimod hydrochloride and preparation method thereof | |
| EP3943095A1 (en) | Traditional chinese medicine laxative composition for treating constipation, preparation method therefor and application thereof | |
| CN101732324B (en) | Levonorgestrel-containing emergency contraception medicament composition and preparation method thereof | |
| CN107616977A (en) | A kind of compound preparation for treating antimigraine and preparation method thereof | |
| CN101152187A (en) | Eplerenone pharmaceutical composition | |
| CN110898024A (en) | Pharmaceutical composition for treating angina pectoris and preparation method thereof | |
| CN115702898B (en) | BTK inhibitor solid preparation and preparation method thereof | |
| CN113081994B (en) | Compound medicine for treating Parkinson's disease and preparation method thereof | |
| CN100427088C (en) | Paracetamol pseudoephedrine hydrochloride and cholrphenamine maleate oral cavity disintegration tablet for treating cold and preparation method thereof | |
| WO2022194198A1 (en) | Lacosamide pharmaceutical composition, preparation method for same, and applications thereof | |
| CN101919799B (en) | Novel sustained-release transdermal medicament delivery system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |